# 此超級綜合評級是基於以下評級的加權平均結果。

*biotech · news · 2026-05-30 · MarketScreener*

## Key points

- Trader 評級使用加權平均，強調 4 個月的每股盈餘修正和估值指標。
- Investor 評級獨特地將 1 年的每股盈餘修正納入其綜合計算。
- 全球綜合評級要求公司至少被五項特定子評級中的四項涵蓋。
- Quality 綜合評級僅在三項品質子評級中至少有兩項存在時才計算。

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-can-ce7f5dd8db89f523)

---

Canonical: https://newsio.io/zh-TW/n/b92f87cf-4bb2-46a5-9de5-ec90764116b7/
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works